


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.37%
-6.95%
-2.37%
-5.45%
-1.52%
ARWR
Arrowhead Pharmaceuticals
$64.64
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
ARWR Price Performance
$64.56 (+0.12%)
$41.5 (+55.76%)
$28.67 (+125.46%)
$18.86 (+242.74%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
ARWR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ARWR Street Sentiment is extremely bullish and have positive views on the near-term outlook
ARWR has Extreme risk level
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Jan 11, 2026
Reiterate
Overweight
Piper Sandler
Dec 12, 2025
Reiterate
Outperform
RBC
Dec 10, 2025
Reiterate
Buy
B of A Securities
Dec 02, 2025
Reiterate
Buy
B of A Securities
Dec 02, 2025
Reiterate
Buy
HC Wainwright & Co.
NVS
Novartis AG
153.95
+0.68%
SNY
Sanofi
47.49
-1.23%
WVE
Wave Life Sciences
12.75
-4.35%
EBS
Emergent Biosolution
10.54
-7.62%
What is ARWR current stock price?
What are ARWR stock strengths?
What is ARWR Risk Level?
What is ARWR market cap and volume?
What is ARWR current Stock IQ?
Should I buy ARWR stock right now?
Is ARWR a Strong Buy right now?
What does a 'Strong Buy' rating mean for ARWR?
What does a 'Strong Sell' rating mean for ARWR?
What factors influence ARWR's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.37%
-6.95%
-2.37%
-5.45%
-1.52%
ARWR
Arrowhead Pharmaceuticals
Current Price
$64.64
Runners Also Watch
NVS
Novartis AG
153.95
+0.68%
SNY
Sanofi
47.49
-1.23%
WVE
Wave Life Sciences
12.75
-4.35%
EBS
Emergent Biosolution
10.54
-7.62%

ARWR Price Performance
$64.56 (+0.12%)
$41.5 (+55.76%)
$28.67 (+125.46%)
$18.86 (+242.74%)
ARWR Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
ARWR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
ARWR Street Sentiment is extremely bullish and have positive views on the near-term outlook
ARWR has Extreme risk level
Risks Indicators

Beta greater than 1.0

High volatilty

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Jan 11, 2026
Reiterate
Overweight
Piper Sandler
Dec 12, 2025
Reiterate
Outperform
RBC
Dec 10, 2025
Reiterate
Buy
B of A Securities
Dec 02, 2025
Reiterate
Buy
B of A Securities
Dec 02, 2025
Reiterate
Buy
HC Wainwright & Co.
ARWR Stock IQ
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
ARWR Latest Analysis
Arrowhead Pharmaceuticals GAAP EPS of $0.22 beats by $0.37 revenue of $264.03M beats by $33.18M.
Thu Feb 5, 2026
Arrowhead Stock Has Skyrocketed 290% in One Year and One Fund Trimmed Its Holdings by $4 Million. Key PointsPrivium Fund Management sold 75747 shares of Arrowhead Pharmaceuticals in the fourth quarter. the estimated transaction value was $3.71 million based on quarterly average prices.
Tue Feb 3, 2026
INEOS GRENADIER OPENS IN ARIZONA WITH ARROWHEAD INEOS GRENADIER. GLENDALE Ariz. Jan. 22 2026 /PRNewswire/ -- INEOS Grenadier is set to open its first dealership in Arizona at INEOS Grenadier Arrowhead. The milestone will be celebrated with a special grand opening event on Thursday January 29 2026 marking a significant expansion of the brands...
Thu Jan 22, 2026
Piper Sandler Highlights Arrowhead Pharmaceuticals Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data. We recently compiled a list of the 15 High Growth Mid-Cap Stocks to Buy. Arrowhead Pharmaceuticals Inc. is among the best high growth stocks. TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100 and reiterated an Overweight rating. The firm mentioned the new release of Redemplo [….]
Thu Jan 22, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ARWR Stock trends
ARWR Stock performance
ARWR Stock analysis
ARWR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.